Abstract
Patients infected with HIV have a high risk of developing dyslipidemia. Effective therapeutic strategies can be challenging due to an increase risk of drug interactions and other comorbidities. Understanding the underlying pathophysiology and the principles of pharmacological and non-pharmacological therapeutic interventions can be of value in the appropriate management of dyslipidemia in the HIV-infected patient.
MeSH terms
-
Anti-HIV Agents / adverse effects
-
Anti-HIV Agents / therapeutic use*
-
Anticholesteremic Agents / therapeutic use*
-
Azetidines / therapeutic use
-
Cholesterol, HDL / metabolism
-
Cholesterol, LDL / metabolism
-
Diet Therapy*
-
Dyslipidemias / complications
-
Dyslipidemias / metabolism
-
Dyslipidemias / therapy*
-
Exercise Therapy*
-
Ezetimibe
-
Fatty Acids, Nonesterified / metabolism
-
Fatty Acids, Omega-3 / therapeutic use
-
Fibric Acids / therapeutic use
-
Glutathione / therapeutic use
-
Growth Hormone-Releasing Hormone / analogs & derivatives
-
Growth Hormone-Releasing Hormone / therapeutic use
-
HIV Infections / complications
-
HIV Infections / drug therapy*
-
HIV Infections / metabolism
-
Human Growth Hormone / therapeutic use
-
Humans
-
Hydroxymethylglutaryl-CoA Reductase Inhibitors
-
Leptin / therapeutic use
-
Niacin / therapeutic use
-
Pyrazines / therapeutic use
-
Thiazolidinediones / therapeutic use
-
Triglycerides / metabolism
Substances
-
Anti-HIV Agents
-
Anticholesteremic Agents
-
Azetidines
-
Cholesterol, HDL
-
Cholesterol, LDL
-
Fatty Acids, Nonesterified
-
Fatty Acids, Omega-3
-
Fibric Acids
-
Hydroxymethylglutaryl-CoA Reductase Inhibitors
-
Leptin
-
Pyrazines
-
Thiazolidinediones
-
Triglycerides
-
Human Growth Hormone
-
Niacin
-
Growth Hormone-Releasing Hormone
-
Ezetimibe
-
Glutathione
-
acipimox
-
tesamorelin